A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
400 patients around the world
Available in Brazil, United States, Mexico, Argentina
Hoffmann-La Roche
18Research sites
400Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Laprida 532 Este, San Juan
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro